Form 4 Filing for Kenneth A. Stauderman

Kenneth A. Stauderman, Chief Scientific Officer at CalciMedica, Inc., was granted 180,000 employee stock options on September 24, 2026. These options, with an exercise price of $1.74, are for CalciMedica's Common Stock and will expire on September 23, 2036. The options begin vesting on September 24, 2026, with 1/48th of the shares vesting monthly over four years. The filing, designated as a Form 4, was signed by John Dunn as Attorney-in-Fact on September 28, 2026. This transaction is classified as the acquisition of a derivative security.